Form 4: Pulmonx CFO Mehul Joshi Reports Stock Transactions

Mehul Joshi, CFO of Pulmonx Corp, reports the sale of shares to cover tax obligations and the acquisition of shares through a stock purchase plan and RSU grant.

Summary

• Mehul Joshi, the Chief Financial Officer & PAO of Pulmonx Corp, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On March 3, 2025, Joshi sold 14,384 shares of common stock at $7.12 per share to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs).
• On the same day, Joshi acquired 108,000 shares through a grant of RSUs.
• These RSUs vest in equal quarterly installments over four years from the grant date of March 3, 2025.
• Joshi also acquired 2,500 shares under the Issuer's 2020 Employee Stock Purchase Plan on February 21, 2025.
• Following these transactions, Joshi beneficially owns 221,986 shares of Pulmonx Corp common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and related to standard executive compensation practices. There's no indication of significant positive or negative sentiment.

Positives

• The acquisition of shares through the Employee Stock Purchase Plan and RSU grant indicates a continued investment and belief in the company's future by the CFO.

Negatives

• The sale of 14,384 shares, although for tax obligations, could be perceived negatively by some investors.

Risks

• There are no specific risks highlighted in this document, but any insider selling can sometimes create short-term market uncertainty.

Future Outlook

The document does not contain specific forward-looking statements about the company's performance, but the vesting schedule of the RSUs suggests a continued commitment from the CFO over the next four years.

Industry Context

Insider transactions are a normal part of corporate governance and are closely watched by investors for signals about a company's prospects. This filing is a routine disclosure and doesn't necessarily indicate a significant shift in the company's outlook.

Comparison to Industry Standards

• Insider trading activity is common across publicly listed companies, and the details of this filing are typical for executives receiving stock-based compensation.
• Companies like Medtronic, Boston Scientific, and Abbott also see regular Form 4 filings from their executives related to stock options, RSU vesting, and ESPP purchases.
• The vesting schedule and tax-related sales are standard practices in executive compensation.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares, but the overall impact is likely to be minimal.

Key Dates